Kuruvilla FG, Schreiber SL. The PIK-related kinases intercept conventional signaling pathways. Chem Biol. 1999;6(5):R129-36. doi:10.1016/S1074-5521(99)80070-2
Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-337.e10. doi:10.1016/j.cell.2018.03.035
Abazeed ME, Adams DJ, Hurov KE, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73(20):6289-98. doi:10.1158/0008-5472.CAN-13-1616
Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell. 1995;82(1):121-30.
Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756-8. doi:10.1038/369756a0
Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell. 1994;76(5):933-45.
Koyama S, Yu H, Dalgarno DC, Shin TB, Zydowsky LD, Schreiber SL. 1H and 15N assignments and secondary structure of the PI3K SH3 domain. FEBS Lett. 1993;324(1):93-8.
Van Stry M, Kazlauskas A, Schreiber SL, Symes K. Distinct effectors of platelet-derived growth factor receptor-alpha signaling are required for cell survival during embryogenesis. Proc Natl Acad Sci U S A. 2005;102(23):8233-8. doi:10.1073/pnas.0502885102
Koyama S, Yu H, Dalgarno DC, Shin TB, Zydowsky LD, Schreiber SL. Structure of the PI3K SH3 domain and analysis of the SH3 family. Cell. 1993;72(6):945-52.
Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378-384. doi:10.1038/nature21386